Glydo (Lidocaine Hydrochloride)

Glydo is supplied as a sterile preparation intended for direct urethral application. The product is instilled into the urethra according to the prescribing information and procedural requirements.

No. Patients with a documented hypersensitivity to lidocaine or other amide‑type local anesthetics should not receive Glydo, as cross‑reactivity may lead to allergic reactions.

Common side effects include transient burning or stinging at the site of application, mild urethral irritation, and temporary urinary urgency. These effects are usually short‑lived.

Serious reactions such as rash, angio‑edema, hypotension, or central nervous system symptoms like seizures should be treated as medical emergencies and prompt evaluation.

The safety of Glydo in pregnancy has not been established. Clinicians should weigh potential benefits against unknown risks and consider alternative anesthesia when possible.

The duration of urethral anesthesia with lidocaine generally ranges from 30 minutes to a few hours, depending on the concentration used and individual patient factors.

Concurrent use of Class I anti‑arrhythmic agents, strong CYP3A4 inhibitors, and other local anesthetics should be avoided because they can increase the risk of systemic toxicity.

Yes. Beta‑blockers and calcium‑channel blockers may potentiate lidocaine’s cardiac effects, so patients on these drugs should be monitored closely.

Glydo should be stored at controlled room temperature, protected from light and moisture, and kept in the original container until use.

Glydo is labeled for adult use; pediatric application should only be considered after careful assessment and under specialist supervision.

If systemic toxicity is suspected—such as dizziness, tinnitus, seizures, or cardiovascular instability—immediate medical intervention is required, including supportive care and, if indicated, administration of lipid emulsion therapy.